EZH2 and Miyoshi myopathy: Moreover, as identified in the HMCLs, a significant correlation between the RNA risk score and the EZH2 inhibitor activity on the primary cells of MM patients was observed (r = −0.91; p-value = 0.0041) (Figure 5B).